View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 12, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		13,398,339
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and Cash Equivalents	$ 1,004,269	$ 766,189
Certificates of Deposit		244,971
Accounts Receivable	315,327	137,499
Notes Receivable	167,512	667,512
Inventories	244,660	265,045
Prepaid Expense and other assets	275,476	289,966
Total Current Assets	2,007,244	2,371,182
Notes Receivable	1,112,524	1,070,000
Equity Method Investment	581,742
Fixed Assets, net	184,385	87,716
Intangibles, net	115,139	95,356
Total Assets	4,001,034	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	165,588	140,462
Accrued Expenses	455,326	785,215
Deferred Revenue	18,342	6,663
Total Liabilities	639,256	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 12,089,446 and 6,943,283 outstanding	120,893	69,432
Additional paid-in capital	(62,138,569)	(57,380,256)
Accumulated Deficit	58,898,477	54,765,045
Total Stockholders' Equity	3,361,778	2,691,914
Total Liabilities and Stockholders' Equity	4,001,034	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		$ 6,479

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	12,089,446	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 358,586	$ 106,822	$ 770,179	$ 281,988
Cost of goods sold	108,970	22,010	226,314	59,003
Gross margin	249,616	84,812	543,865	222,985
General and administrative expense	729,528	2,214,705	1,945,670	3,346,777
Operations expense	378,906	182,507	666,496	383,001
Sales and marketing expense	554,084	231,270	1,104,623	378,724
Total Expense	1,662,518	2,628,482	3,716,789	4,108,502
Loss on equity method investment	(960,508)		(960,508)
Net loss attributable to common shareholders	(2,373,410)	(2,543,670)	(4,133,432)	(3,885,517)
Comprehensive loss	$ (2,373,410)	$ (2,543,670)	$ (4,133,432)	$ (3,885,517)
Loss per common share - basic and diluted (in dollars per share)	$ (0.20)	$ (0.41)	$ (0.36)	$ (0.62)
Weighted average shares used in computation - basic and diluted (in shares)	11,878,490	6,167,689	11,632,221	6,308,554

Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Retained Earnings [Member]	Consulting Agreement Two [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]	Investor Relations Consultant [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Investor Relations Consultant [Member] Preferred Stock [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member] Retained Earnings [Member]	Investor Relations Consultant [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member]	Re-priced Warrants [Member] Common Stock [Member]	Re-priced Warrants [Member] Additional Paid-in Capital [Member]	Re-priced Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2016																											$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Balance (in shares) at Dec. 31, 2016																										79,246		4,564,428
Shares issued pursuant to the public offering	$ 1,750	$ 392,000		$ 393,750																								$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)	175,000																											1,750,000
Vesting Expense																													2,131,821			2,131,821
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																												$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																												(400,000)
Shares issued for services					$ 1,000	$ 219,000	$ 220,000							$ 792	$ 61,894	$ 54,040,705	$ (50,903,968)	$ 3,199,423
Shares issued for services (in shares)					100,000								79,246		6,189,428
Unrealized (loss) from marketable securities																															(1,501)	(1,501)
Net loss								$ (3,885,517)	$ (3,885,517)
Net loss								$ (3,885,517)	$ (3,885,517)
Balance at 1/1/2018 at Dec. 31, 2017																											7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Balance at 1/1/2018 (in shares) at Dec. 31, 2017																									647,819	79,246		6,943,283
Shares issued pursuant to the public offering	$ 2,153	$ 202,268	$ 1	$ 204,422																								$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)	215,247																											2,900,000
Vesting Expense																													460,368			460,368
Net loss																														(4,133,432)		(4,133,432)
Preferred conversion to common shares pursuant to private placement agreement																											(6,479)	$ 5,897	582			0
Preferred conversion to common shares pursuant to private placement agreement (in shares)																									(647,819)			589,747
Investment pursuant to Helomics 20% acquisition										$ 11,000	$ 1,031,250	$ 1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)										1,100,000
Warrant exercises																			$ 888	$ 87,948	$ 88,836	$ 2,523	$ 249,810	$ 252,333
Warrant exercises (in shares)																			88,836			252,333
Net loss																														(4,133,432)		(4,133,432)
Balance at 1/1/2018 at Jun. 30, 2018																											$ 792	$ 120,893	$ 62,138,569	$ (58,898,476)		$ 3,361,778
Balance at 1/1/2018 (in shares) at Jun. 30, 2018																										79,246		12,089,446

Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Jun. 30, 2018 $ / shares
Series E Warrants [Member] \| Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Common Stock [Member] \| Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	0.9497
Warrant exercises, exercise price per share (in dollars per share)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities:
Net loss	$ (4,133,432)	$ (3,885,517)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	960,508
Depreciation and amortization	41,062	35,995
Vested stock options and warrants	460,368	2,131,821
Equity instruments issued for management and consulting		216,000
Loss from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(177,828)	(6,085)
Inventories	20,385	30,004
Prepaid expense and other assets	14,490	(39,892)
Accounts payable	25,126	(162,685)
Accrued expenses	(329,889)	(394,767)
Deferred revenue	11,679	6,159
Net cash used in operating activities:	(3,107,531)	(2,070,804)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,593,174)
Redemption of certificates of deposit	244,971
Advance on notes receivable	(42,524)
Purchase of fixed assets	(129,990)	(38,637)
Purchase of intangibles	(27,524)	(1,229)
Net cash provided by (used in) investing activities:	44,933	(2,348,375)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	341,169
Issuance of common stock	2,959,509	3,814,938
Net cash provided by financing activities	3,300,678	3,814,938
Net increase (decrease) in cash and cash equivalents	238,080	(604,241)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	1,004,269	1,159,849
Non-cash transactions:
Conversion of Preferred Stock to Common Stock	6,479
Equity method investment - Helomics	$ 1,542,250

Note 1 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

June 30, 2018,

the Company had

12,089,446

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

) the Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of proprietary cleaning fluid and filters to users of its systems. In

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc., to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the

first

quarter, is presented as part of the condensed consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of

$58,898,477.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. The Company had cash and cash equivalents of

$1,004,269

as of

June 30, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

June 30, 2018,

the Company has raised approximately

$35,840,380

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock, (

)

$2,755,000

from a firm commitment underwritten public offering, and (

)

$5,685,000

in debt financing.

Interim Financial Statements

The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do

not

result in consolidation and are

not

accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of

January 1, 2018.

As of

June 30, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

Early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact that the updated standard will have on the Company’s financial statements.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.

Accounting Policies and Estimates

The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	June 30, 2018		December 31, 2017

Finished goods	$	31,782	$	62,932
Raw materials		168,735		141,028
Work-In-Process		44,143		61,085
Total	$	244,660	$	265,045

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	June 30, 2018		December 31, 2017
Computers and office equipment	$	201,123	$	183,528
Leasehold improvements		122,188		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		59,210		43,368
Total		491,476		361,486
Less: Accumulated depreciation		307,091		273,770
Total Fixed Assets, Net	$	184,385	$	87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was

$18,825

and

$33,321

in the

three

and

six

months ended

June 30, 2018

and was

$14,519

and

$30,204

for the

three

and

six

months ended

June 30, 2017.

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$4,070

and

$7,741

in the

three

and

six

months ended

June 30, 2018

and was

$2,902

and

$5,790

in the

three

and

six

months ended

June 30, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The “PCT” allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

countries of the PCT, including the United States. Filing this single “international” patent application through the PCT is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired.

The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

the Company filed an international PCT patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. The Company anticipates that the favorable International Search Report will result in allowance of its various national applications.

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651

and has sent a Notice of Intent to Grant. The Company is now in the process of identifying the key European countries that it will validate the patent in.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has a credit risk concentration because of depositing

$794,125

of funds in excess of insurance limits in a single bank.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

and

six

months ended

June 30, 2018

and

2017

were located at or derived from operations in the United States. There was

$3,178

and

in revenues from sales outside the United States during the

three

-month period of

2018

and

2017,

respectively; and

$5,866

and

$26,662

in revenues from sales outside of the United States during the

first

six

months of

2018

and

2017,

respectively.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 Equity Method Investment

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. The unaudited

six

-month condensed statement of operations is as follows:

Helomics Holdings Corporation

	For the Six Months Ended
	June 30, 2018
Revenue	$	118,697

Gross margin	$	(25,539	)


Net loss from continuing operations	$	(4,285,054	)

Net loss to investee	$	(3,324,546	) 1

The loss to investee was calculated at

80%

for the initial period of ownership,

January 11, 2018 –

February 27, 2018,

and then at

75%

for the remainder of the

six

-month period at the current equity investment percentage owned by the Company.

Helomics’

first

six

months included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have therefore

not

yet generated any revenues. Additionally, there was a

$1.2M

one

-time expense for the conversion of notes payable into new notes that carry interest and warrants.

Note 3 - Revenue Recognition	6 Months Ended
Note 3 - Revenue Recognition	Jun. 30, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2018, and December 31, 2017, accounts receivable totaled $315,327 and $137,499, respectively. For the three and six months ended June 30, 2018, the Company did not incur material impairment losses with respect to its receivables. The Company deferred revenues related primarily to maintenance plans of $18,342 and $6,663 as of June 30, 2018 and December 31, 2017, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 4 - Stockholders' Equity, Stock Options and Warrants

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

2018

Firm Commitment Public Offering

January 2018,

the Company completed a firm commitment underwritten public offering of

2,900,000

Units at an offering price of

$0.95

per Unit, with each Unit consisting of

one

share of the Company’s common stock and

0.3

of a Series E Warrant, with each whole Series E Warrant purchasing

one

share of common stock at an exercise price of

$1.00

per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately

$2,755,000,

before deducting expenses. The Company granted the underwriter a

-day option to purchase an additional (i) up to

290,000

additional shares of Common Stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to

87,000

additional shares of common stock at a purchase price of

$0.001

per Series E Warrant to cover over-allotments, if any. On

February 21, 2018,

the underwriter exercised on

215,247

shares of common stock, par value

$0.01,

$0.9497

per share as described in the Underwriting Agreement. The Company received net proceeds of

$188,066

after deductions of

$16,354

representing the underwriter’s discount of

of the purchase price of the shares.

Share Exchange Agreement With Helomics

January 11, 2018,

the Company entered into a share exchange agreement with Helomics Holding Corporation (“Helomics”). Pursuant to the share exchange agreement, Helomics issued

2,500,000

shares of its Series A Preferred Stock in exchange for

1,100,000

shares of common stock. Under the share exchange agreement, in

March 2018

the Company converted

$500,000

in secured notes into another

of Helomics’ outstanding shares, which resulted in the Company owning

25%

of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of

$500,000

to Helomics. The

1,100,000

shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Precision Therapeutic shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Precision Therapeutic shares will be released to Helomics following a determination that Helomics’ revenues in any

-month period have been equal or greater than

$8,000,000.

The Helomics Preferred Stock issued to the Company is convertible into an aggregate of

20%

of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics

may

take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

Merger Agreement with Helomics

June 28, 2018,

the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. The Merger Agreement contemplates a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock

not

already held by the Company will be converted into the right to receive a proportionate share of

7.5

million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the

1.1

million shares of the Company’s common stock already issued to Helomics for the Company’s initial

20%

ownership in Helomics. Additionally,

860,000

shares of the merger consideration are to be held in escrow for

months to satisfy indemnification claims. Helomics currently has outstanding

$7.6

million in promissory notes and warrants to purchase

18.7

million shares at an exercise price of

$1.00

per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to

5.0

million additional shares of Helomics common stock at an exercise price of

$1.00

per share. Helomics agrees to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least

75%

of the

$7.6

million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of

0.6

Precision warrants for each Helomics warrant, with an exercise price of

$1.00

per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated

23.7

million shares of the Company’s common stock and warrants to purchase an additional

14.2

million shares of the Company’s common stock at

$1.00

per share. In addition, Helomics currently has

995,000

warrants held by other parties at an exercise price of

$0.01

per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase

597,000

shares of Precision common stock at

$0.01

per share.

Completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.

Increases in Authorized Shares

At a special meeting of the stockholders on

January 29, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has

significant public trading history, and the Company has experienced

significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of

years of

small-cap medical companies traded on major exchanges and

mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

Since the Company has limited trading history in its stock and

first

-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.

Valuation and accounting for options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

January 15, 2018,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

50,000

shares of common stock, par value

$0.01

$0.97

per share to the Company’s newly hired International Vice President of Sales. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

March 12, 2018,

the Company issued inducement stock options in accordance with NASDAQ rule for

111,112

shares of common stock, par value

$0.01

$1.35

per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

For grants of stock option and warrants in

2018

the Company used

2.33%

3.00%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.4816

$1.0044

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		482,402			1.11		957,000			1.00
Expired		(127,130	)		2.22		(10,706	)		199.55
Exercised		-			-		(341,169	)		1.00

Outstanding at June 30, 2018		3,120,255		$	1.85		2,556,382		$	5.97

June 30, 2018,

2,154,442

stock options are fully vested and currently exercisable with a weighted average exercise price of

$2.05

and a weighted average remaining term of

9.40

years. There are

2,556,382

warrants that are fully vested and exercisable. Stock-based compensation recognized for the

six

months ended

June 2018

and

June 2017

was

$460,368

and $(

18,276

), respectively. The Company has

$997,772

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

June 30, 2018:

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.80
$	0.965		3,000		9.88
$	0.97		191,753		9.52
$	1.01		124,358		9.51
$	1.10		22,730		9.76
$	1.13		143,807		10.00
$	1.35		111,112		9.71
$	1.454		17,200		9.26
$	1.47		2,373,226		8.99
$	2.10		14,286		8.76
$	2.25		293		8.16
$	2.42		20,640		8.14
$	2.80		57,145		8.51
$	3.75		3,998		8.01
$	4.125		3,636		8.26
$	4.1975		7,147		8.22
$	4.25		3,529		7.76
$	5.125		3,902		8.19
$	65.75		190		7.32
$	73.50		1,157		7.51
$	77.50		2,323		7.01
$	80.25		187		7.26
$	86.25		232		6.76
$	131.25		81		4.19
$	148.125		928		4.72
$	150.00		1,760		4.13
$	162.50		123		6.51
$	206.25		121		6.26
$	248.4375		121		5.04
$	262.50		130		5.04
$	281.25		529		4.55
$	318.75		3		4.86
$	346.875		72		5.76
$	431.25		306		5.69
$	506.25		188		5.51
$	596.25		42		5.25

			3,120,255

Warrants
$	1.00		1,372,828		4.36
$	1.07		697,946		4.35
$	2.25		385,000		3.57
$	123.75		94,084		2.17
$	243.75		2,529		1.10
$	309.375		2,850		1.11
$	309.50		222		1.36
$	506.25		59		0.63
$	609.375		862		0.60
			2,556,382

At the annual meeting on

December 28, 2017,

the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to

5,000,000,

(ii) increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. As described in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting on

July 28, 2016

but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

June 30, 2018

by year of grant:

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,553	148.13	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		100,292	2.25	–	5.13
2017		2,529,070	1.01	–	2.10
2018		482,402	0.91	–	1.35
Total		3,120,255	$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455	$243.75	–	$609.38
2015		94,151	0.00	–	243.75
2016		504,666		1.00
2017		1,082,946	1.07	–	2.25
2018		868,164		1.00
Total		2,556,382	$0.00	–	$609.38

Note 5 - Notes Receivable	6 Months Ended
Note 5 - Notes Receivable	Jun. 30, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 – NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen as fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics Corporation. The Company now has an equity stake in Helomics totaling 25%. The Company is currently negotiating terms for payment on the remaining $167,512 plus interest. Upon completion of the merger with Helomics the note would be eliminated on a consolidated basis.

Note 6 - Loss Per Share

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,373,410	)	$	(2,543,670	)	$	(4,133,432	)	$	(3,885,517	)
Comprehensive loss		(2,373,410	)		(2,543,670	)		(4,133,432	)		(3,885,517	)
Denominator:
Weighted average common shares outstanding-basic		11,878,490			6,167,689			11,632,221			6,308,554

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		11,878,490			6,167,689			11,632,221			6,308,554

Loss per common share-basic and diluted	$	(0.20	)	$	(0.41	)	$	(0.36	)	$	(0.62	)

(

) The number of shares underlying options and warrants outstanding as of

June 30, 2018

and

June 30, 2017

are

5,676,637

and

3,850,878,

respectively. The number of shares underlying the preferred stock as of

June 30, 2018

79,246.

The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 7 - Related Party Transactions	6 Months Ended
Note 7 - Related Party Transactions	Jun. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 7 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In April 2018, one of the Company’s directors, Richard L. Gabriel, executed a six -month consulting contract to help guide operations for the Company’s wholly-owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 monthly cash payment. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement.

Note 8 - Subsequent Events	6 Months Ended
Note 8 - Subsequent Events	Jun. 30, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 8 – SUBSEQUENT EVENTS On July 13, 2017, the Company received letters from an attorney on behalf of stockholders alleging that a proposal seeking stockholder approval of various amendments to the Company’s Amended and Restated 2012 Stock Incentive Plan (the “Plan”), including an increase in the shares reserved under the Plan, which was voted on by the Company’s stockholders at its 2016 annual stockholders’ meeting on July 28, 2016, was not duly approved under the applicable voting standard. The Company cured the situation promptly by responsive actions, and in December 2017, the stockholders approved an amendment to the Plan in compliance with the applicable voting standard. In July 2018, the Company settled all legal claims there is no further liability remaining.

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

June 30, 2018,

the Company had

12,089,446

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare company that provides personalized medicine solution and medical devices in

two

main areas: (

) precision medicine, which aims to apply artificial intelligence to personalized medicine and drug discovery; and (

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

149,000

first

quarter, is presented as part of the condensed consolidated financial statements (“financial statements”).

$58,898,477.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. The Company had cash and cash equivalents of

$1,004,269

as of

June 30, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

June 30, 2018,

the Company has raised approximately

$35,840,380

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock, (

)

$2,755,000

from a firm commitment underwritten public offering, and (

)

$5,685,000

in debt financing.

Interim Financial Statements, Policy [Policy Text Block]

Interim Financial Statements

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

January 1, 2018.

As of

June 30, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact that the updated standard will have on the Company’s financial statements.

Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Use of Estimates, Policy [Policy Text Block]

Accounting Policies and Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit Policy [Policy Text Block]

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	June 30, 2018		December 31, 2017

Finished goods	$	31,782	$	62,932
Raw materials		168,735		141,028
Work-In-Process		44,143		61,085
Total	$	244,660	$	265,045

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		3
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s fixed assets consist of the following:

	June 30, 2018		December 31, 2017
Computers and office equipment	$	201,123	$	183,528
Leasehold improvements		122,188		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		59,210		43,368
Total		491,476		361,486
Less: Accumulated depreciation		307,091		273,770
Total Fixed Assets, Net	$	184,385	$	87,716

Depreciation expense was

$18,825

and

$33,321

in the

three

and

six

months ended

June 30, 2018

and was

$14,519

and

$30,204

for the

three

and

six

months ended

June 30, 2017.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$4,070

and

$7,741

in the

three

and

six

months ended

June 30, 2018

and was

$2,902

and

$5,790

in the

three

and

six

months ended

June 30, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Offering Costs [Policy Text Block]

Offering Costs

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The “PCT” allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651

and has sent a Notice of Intent to Grant. The Company is now in the process of identifying the key European countries that it will validate the patent in.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has a credit risk concentration because of depositing

$794,125

of funds in excess of insurance limits in a single bank.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

and

six

months ended

June 30, 2018

and

2017

were located at or derived from operations in the United States. There was

$3,178

and

in revenues from sales outside the United States during the

three

-month period of

2018

and

2017,

respectively; and

$5,866

and

$26,662

in revenues from sales outside of the United States during the

first

six

months of

2018

and

2017,

respectively.

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 1 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30, 2018		December 31, 2017

Finished goods	$	31,782	$	62,932
Raw materials		168,735		141,028
Work-In-Process		44,143		61,085
Total	$	244,660	$	265,045

Property Plant and Equipment UsefulLife [Table Text Block]

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td> </td> <td colspan="3" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Years</div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Computers and office equipment</div></td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">-</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 86%"><div style="display: inline; font-size: 10pt">Leasehold improvements</div></td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 3%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="width: 5%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Manufacturing tooling</div></td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">-</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td><div style="display: inline; font-size: 10pt">Demo equipment</div></td> <td> </td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>

Property, Plant and Equipment [Table Text Block]

	June 30, 2018		December 31, 2017
Computers and office equipment	$	201,123	$	183,528
Leasehold improvements		122,188		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		59,210		43,368
Total		491,476		361,486
Less: Accumulated depreciation		307,091		273,770
Total Fixed Assets, Net	$	184,385	$	87,716

Note 2 Equity Method Investment (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Equity Method Investments [Table Text Block]

Helomics Holdings Corporation

	For the Six Months Ended
	June 30, 2018
Revenue	$	118,697

Gross margin	$	(25,539	)


Net loss from continuing operations	$	(4,285,054	)

Net loss to investee	$	(3,324,546	) 1

Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Share-based Compensation, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		482,402			1.11		957,000			1.00
Expired		(127,130	)		2.22		(10,706	)		199.55
Exercised		-			-		(341,169	)		1.00

Outstanding at June 30, 2018		3,120,255		$	1.85		2,556,382		$	5.97

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.91		10,000		9.80
$	0.965		3,000		9.88
$	0.97		191,753		9.52
$	1.01		124,358		9.51
$	1.10		22,730		9.76
$	1.13		143,807		10.00
$	1.35		111,112		9.71
$	1.454		17,200		9.26
$	1.47		2,373,226		8.99
$	2.10		14,286		8.76
$	2.25		293		8.16
$	2.42		20,640		8.14
$	2.80		57,145		8.51
$	3.75		3,998		8.01
$	4.125		3,636		8.26
$	4.1975		7,147		8.22
$	4.25		3,529		7.76
$	5.125		3,902		8.19
$	65.75		190		7.32
$	73.50		1,157		7.51
$	77.50		2,323		7.01
$	80.25		187		7.26
$	86.25		232		6.76
$	131.25		81		4.19
$	148.125		928		4.72
$	150.00		1,760		4.13
$	162.50		123		6.51
$	206.25		121		6.26
$	248.4375		121		5.04
$	262.50		130		5.04
$	281.25		529		4.55
$	318.75		3		4.86
$	346.875		72		5.76
$	431.25		306		5.69
$	506.25		188		5.51
$	596.25		42		5.25

			3,120,255

Warrants
$	1.00		1,372,828		4.36
$	1.07		697,946		4.35
$	2.25		385,000		3.57
$	123.75		94,084		2.17
$	243.75		2,529		1.10
$	309.375		2,850		1.11
$	309.50		222		1.36
$	506.25		59		0.63
$	609.375		862		0.60
			2,556,382

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,553	148.13	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		100,292	2.25	–	5.13
2017		2,529,070	1.01	–	2.10
2018		482,402	0.91	–	1.35
Total		3,120,255	$0.91	–	$596.25

Warrants:
Year	Shares		Price
2014		6,455	$243.75	–	$609.38
2015		94,151	0.00	–	243.75
2016		504,666		1.00
2017		1,082,946	1.07	–	2.25
2018		868,164		1.00
Total		2,556,382	$0.00	–	$609.38

Note 6 - Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Numerator
Net loss available in basic and diluted calculation	$	(2,373,410	)	$	(2,543,670	)	$	(4,133,432	)	$	(3,885,517	)
Comprehensive loss		(2,373,410	)		(2,543,670	)		(4,133,432	)		(3,885,517	)
Denominator:
Weighted average common shares outstanding-basic		11,878,490			6,167,689			11,632,221			6,308,554

Effect of diluted stock options, warrants and preferred stock (1)		-			-			-			-

Weighted average common shares outstanding-basic		11,878,490			6,167,689			11,632,221			6,308,554

Loss per common share-basic and diluted	$	(0.20	)	$	(0.41	)	$	(0.36	)	$	(0.62	)

Note 1 - Summary of Significant Accounting Policies (Details Textual)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended	196 Months Ended
	Jan. 31, 2018 USD ($)	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018	Feb. 21, 2018 $ / shares	Dec. 28, 2017 $ / shares	Dec. 31, 2016 USD ($)
Common Stock, Shares, Outstanding, Ending Balance \| shares		12,089,446		12,089,446		6,943,283	12,089,446
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01		$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance		$ (58,898,477)		$ (58,898,477)		$ (54,765,045)	$ (58,898,477)
Cash and Cash Equivalents, at Carrying Value, Ending Balance		1,004,269	$ 1,159,849	1,004,269	$ 1,159,849	766,189	1,004,269				$ 1,764,090
Stockholders' Equity, Period Increase (Decrease), Total							35,840,380
Stock Issued During Period, Value, New Issues				2,755,087		3,421,188
Debt Instrument, Increase (Decrease), Net, Total							$ 5,685,000
Depreciation, Total		18,825	14,519	33,321	30,204
Amortization of Intangible Assets, Total		4,070	2,902	7,741	5,790
Income Tax Expense (Benefit), Total		$ 0	0	$ 0	0
Valuation Allowance Percentage		100.00%		100.00%			100.00%
Unrecognized Tax Benefits, Ending Balance		$ 0		$ 0			$ 0
Cash, Uninsured Amount		794,125		$ 794,125			794,125
Number of Operating Segments				2
Non-US [Member]
Revenues, Total		$ 3,178	$ 0	$ 5,866	$ 26,662
Earliest Tax Year [Member]
Open Tax Year				2014
IPO [Member]
Stock Issued During Period, Value, New Issues							13,555,003
Proceeds from Issuance or Sale of Equity, Total							3,937,500
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs							1,739,770
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues				$ 204,422		$ 393,750
Proceeds from Issuance or Sale of Equity, Total							358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 2,755,000						2,755,000
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues							2,055,000
Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues							$ 1,300,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest								25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Finished goods	$ 31,782	$ 62,932
Raw materials	168,735	141,028
Work-In-Process	44,143	61,085
Total	$ 244,660	$ 265,045

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	6 Months Ended
	Jun. 30, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 491,476	$ 361,486
Less: Accumulated depreciation	307,091	273,770
Total Fixed Assets, Net	184,385	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	201,123	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	122,188	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 59,210	$ 43,368

Note 2 Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	80.00%
Debt Conversion, One-time Expense	$ 1.2

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) - Helomics Holding Corp. [Member]

6 Months Ended

Jun. 30, 2018

USD ($)

Revenue

$ 118,697

Gross margin

(25,539)

Net loss from continuing operations

(4,285,054)

Net loss to investee

$ (3,324,546)

^[1]

[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the six-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 315,327	$ 137,499
Contract with Customer, Liability, Current	$ 18,342	$ 6,663
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual)						1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended	196 Months Ended
	Jun. 28, 2018 USD ($) $ / shares shares	Mar. 12, 2018 $ / shares shares	Feb. 21, 2018 USD ($) $ / shares shares	Jan. 15, 2018 $ / shares shares	Jan. 11, 2018 USD ($) shares	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($)	Dec. 31, 2017 $ / shares shares	Jun. 30, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) shares	Jan. 02, 2018 shares	Dec. 28, 2017 $ / shares shares	Jan. 29, 2017 shares	Oct. 27, 2016 shares
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01			$ 0.01
Common Stock, Shares Authorized							50,000,000	50,000,000		50,000,000	50,000,000			50,000,000	24,000,000	8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate								0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number								2,154,442			2,154,442
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares								$ 2.05			$ 2.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term								9 years 146 days
Class of Warrant or Right Number of Warrants Vested and Exercisable								2,556,382			2,556,382
Allocated Share-based Compensation Expense, Total \| $								$ 460,368	$ 18,276
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $								$ 997,772			$ 997,772
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $							$ 1,900,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								482,402		2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares								$ 1.11		$ 1.45
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								1 year 120 days
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares				$ 0.97
Number of Equal Installments Options are Expected to Vest				4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares		$ 1.35
Number of Equal Installments Options are Expected to Vest		4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								$ 609.38			$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares								$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								3.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares								$ 1.0044
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								0			$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares								$ 0.91
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								2.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term								5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares								$ 0.4816
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													5,000,000
Helomics Holding Corp. [Member]
Notes Payable, Total \| $	$ 7,600,000
Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues					1,100,000
Share Exchange Agreement, Shares Received					2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $												$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock												5.00%
Share Exchange Agreement, Potential Interest												25.00%
Share Exchange Agreement, Number of Shares Held in Escrow												1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum \| $					$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent					20.00%
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price \| $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues						2,900,000
Share Price \| $ / shares						$ 0.95
Proceeds from Issuance or Sale of Equity, Total \| $						$ 2,755,000					$ 2,755,000
The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit						0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues			215,247
Proceeds from Issuance or Sale of Equity, Total \| $											$ 358,312
Sale of Stock, Underwriter Option Term						45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase						290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase						87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares						$ 0.001
Shares Issued, Price Per Share \| $ / shares			$ 0.9497
Proceeds from Underwriter Shares Exercised, Net \| $			$ 188,066
Stock Issued During Period, Underwriter Discount \| $			$ 16,354
Underwriter Discount Percentage			8.00%

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,120,255
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22
Number of Shares Issued (in shares)	957,000	1,082,946
Average Exercise Price Issued (in dollars per share)	$ 1	$ 1.49
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(341,169)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	2,556,382	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 5.97	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	482,402	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.11	$ 1.45
Number of Shares Expired (in shares)	(127,130)	(12,730)
Average Exercise Price Expired (in dollars per share)	$ 2.22	$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	3,120,255	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.85	$ 2

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Shares, options (in shares)	3,120,255
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares
Shares, warrants (in shares)	2,556,382
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 1
Shares, warrants (in shares)	1,372,828
Weighted average remaining life, warrants (Year)	4 years 131 days
Warrant Two [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	4 years 127 days
Warrant Three [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 208 days
Warrant Four [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	2 years 62 days
Warrant Five [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	1 year 36 days
Warrant Six [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	1 year 40 days
Warrant Seven [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	1 year 131 days
Warrant Eight [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	229 days
Warrant Nine [Member]
Warrant exercises, exercise price per share (in dollars per share) \| $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	219 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.91
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 292 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.965
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 321 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 189 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.01
Shares, options (in shares)	124,358
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.10
Shares, options (in shares)	22,730
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.13
Shares, options (in shares)	143,807
Weighted average remaining life, options (Year)	10 years
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 259 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	9 years 94 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.47
Shares, options (in shares)	2,373,226
Weighted average remaining life, options (Year)	8 years 361 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 277 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	8 years 58 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.42
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	8 years 51 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 3.75
Shares, options (in shares)	3,998
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	8 years 94 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	8 years 80 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	8 years 69 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	7 years 116 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	7 years 94 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	4 years 69 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 262 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	4 years 47 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 94 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 14 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	5 years 14 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 200 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 313 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 251 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 186 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years 91 days

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Shares, options (in shares) \| shares	3,120,255
Shares, warrants (in shares) \| shares	2,556,382
Warrant exercises, exercise price per share (in dollars per share)
Minimum [Member]
Price, options (in dollars per share)	0.91
Warrant exercises, exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares) \| shares	6,455
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) \| shares	94,151
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) \| shares	504,666
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	868,164
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2018 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)
Warrants 2018 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)
Stock Options 2011 [Member]
Shares, options (in shares) \| shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	836
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	100,292
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	2,529,070
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	482,402
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.91
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended
Note 5 - Notes Receivable (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Oct. 31, 2017	Jul. 31, 2017
Advance to Helomics [Member]
Payments to Acquire Notes Receivable			$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable		$ 67,512
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage	8.00%			8.00%
Financing Receivable, Net, Total	$ 1,112,524	$ 1,070,000
Notes Receivable, Term	2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total	$ 167,512
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock	5.00%
Investment, Ownership Percent	25.00%

Note 6 - Loss Per Share (Details Textual) - shares	6 Months Ended
Note 6 - Loss Per Share (Details Textual) - shares	Jun. 30, 2018	Jun. 30, 2017
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,676,637	3,850,878
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 6 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

6 Months Ended

Jun. 30, 2018

Jun. 30, 2017

Jun. 30, 2018

Jun. 30, 2017

Net loss available in basic and diluted calculation

$ (2,373,410)

$ (2,543,670)

$ (4,133,432)

$ (3,885,517)

Weighted average common shares outstanding-basic (in shares)

11,878,490

6,167,689

11,632,221

6,308,554

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

^[1]

Loss per common share - basic and diluted (in dollars per share)

$ (0.20)

$ (0.41)

$ (0.36)

$ (0.62)

[1]

The number of shares underlying options and warrants outstanding as of June 30, 2018 and June 30, 2017 are 5,693,808 and 3,850,878, respectively. The number of shares underlying the preferred stock as of June 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 7 - Related Party Transactions (Details Textual) - Director [Member]	1 Months Ended
	Apr. 30, 2018 USD ($) shares
Related Party Transaction, Monthly Cash Payment \| $	$ 12,000
Restricted Stock Units (RSUs) [Member] \| Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	240,000